What is it about?
The lack of effective and safe analgesics for chronic pain management has been a health problem associated with people’s livelihoods for many years. Programmed cell death protein 1 (PD-1) is widely expressed in neurons and participates in the modulation of neuronal excitability, synaptic transmission, and synaptic plasticity. In this work, we screened an analgesic peptide H-20, which significantly inhibits acute pain and chronic pain via the PD-1 pathway with few adverse effects in multiple preclinical pain models.
Photo by ilgmyzin on Unsplash
Why is it important?
Our findings show that analgesic peptide H-20 is a promising candidate analgesic drug. Furthermore, our work confirms that developing a new analgesic therapy using PD-1 signaling to therapeutically alleviate chronic pain is feasible and worthy of future research.
Read the Original
This page is a summary of: An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects, Proceedings of the National Academy of Sciences, July 2022, Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.2204114119.
You can read the full text:
The following have contributed to this page